U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H31N5O10P2
Molecular Weight 647.5101
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BR-007

SMILES

OC(CCCNC(=O)OCCOC1=CC2=C(C=C1)C(=CC=N2)C3=C4CCCN4N=C3C5=CC=CC=N5)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=AKZVACKATXEQQW-UHFFFAOYSA-N
InChI=1S/C27H31N5O10P2/c33-26(30-12-4-10-27(34,43(35,36)37)44(38,39)40)42-16-15-41-18-7-8-19-20(9-13-29-22(19)17-18)24-23-6-3-14-32(23)31-25(24)21-5-1-2-11-28-21/h1-2,5,7-9,11,13,17,34H,3-4,6,10,12,14-16H2,(H,30,33)(H2,35,36,37)(H2,38,39,40)

HIDE SMILES / InChI
Molecular Formula C27H31N5O10P2
Molecular Weight 647.5101
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

TGF-B-recpotor inhibitor (dihydropyrrolopyrazole, 13) is one of the series of optimized, bioavailable dihydropyrrolopyrazole TGF-beta receptor type I inhibitors synthesized at Ely Lilly and is an investigational antitumor agent.

Originator

Eli Lilly
237
Curator's Comment: # Eli Lilly

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
TGF-beta receptor type-1
8
Target ID: P36897
Gene ID: 7046.0
Gene Symbol: TGFBR1
Target Organism: Homo sapiens (Human)
Inhibitor
8297
 160.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
2004 Jul 5
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
2008 Apr 10

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Antiproliferative activity against mouse NIH3T3 cells by [3H]thymidine assay of TGF-B-recpotor inhibitor (compound 13) had IC50 of 420±410 nM. EC50 of 200±73 nM value was obtained from luciferase reporter assay in mink mink lung epithelial Mv1Lu p3TP-Lux stable transfectants.
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:14:41 GMT 2023
Edited
by admin
on Sat Dec 16 19:14:41 GMT 2023
Record UNII
87VER89275
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BR-007
Code English
(1-hydroxy-4-(((2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethoxy)carbonyl)amino)butane-1,1-diyl)bis(hydrogen phosphonate)
Common Name English
BR007
Code English
Code System Code Type Description
CAS
2409546-40-1
Created by admin on Sat Dec 16 19:14:41 GMT 2023 , Edited by admin on Sat Dec 16 19:14:41 GMT 2023
PRIMARY
PUBCHEM
156766559
Created by admin on Sat Dec 16 19:14:41 GMT 2023 , Edited by admin on Sat Dec 16 19:14:41 GMT 2023
PRIMARY
FDA UNII
87VER89275
Created by admin on Sat Dec 16 19:14:41 GMT 2023 , Edited by admin on Sat Dec 16 19:14:41 GMT 2023
PRIMARY
Related Record Type Details
Structure of BR-007 Sodium
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
Structure of 2-[[4-[5,6-Dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]ethanol
ACTIVE MOIETY (FOR EXCLUSIVITY)
Structure of 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966